CAR-T Therapy: EULAR 2026 Conference Recap Save

I. THE COMPARE TRIAL: CD19 CAR-T REACHES THE RHEUMATOID SYNOVIUM

The SLE CAR-T research set the stage. EULAR 2026 brought the first prospective interventional trial of CD19 CAR-T therapy in RA: six patients, one infusion, and rigorous mechanistic analyses including  synovial biopsies, 68Ga-FAPI PET, and paired autoantibody profiling before and after. The COMPARE Phase 1 confirmed that CD19 CAR-T cells reach the joint, clear autoreactive B-cell clones at tissue level, and allow complete DMARD discontinuation in a cohort that had failed a median of six prior b/tsDMARDs. Whether this is prologue or proof of concept depends on the Phase 2 readout against rituximab — but the question is no longer theoretical.

CAR-T Reaches the Synovium: COMPARE Phase 1 in ACPA-Positive RA

Immune Dimming or Immune Reset in RA: How Far Should We Go?

CAR-T For Rheumatoid Arthritis

CAR-T Topic Panel: EULAR 2026

CAR-T Topic Compilation Podcast

Conclusions:

The COMPARE data are small but mechanistically rich. For the first time, there is prospective evidence that CD19 CAR-T depletes autoreactive CCP4-reactive memory B cells in the synovium, not just in peripheral blood — and that reconstitution produces a naïve, less autoreactive repertoire. Autoantibody reduction was sustained in four of six patients for ACPA and five of six for RF-IgM. The Phase 2 randomized comparison against rituximab is already enrolling. For the practicing rheumatologist, the practical window remains narrow: this is for the ACPA-positive patient who has exhausted multiple b/tsDMARD classes, not the patient who has failed two biologics. The Phase 2 readout will determine whether COMPARE becomes a referral pathway or stays a proof of concept.

II. BEYOND CD19: EXPANDING TARGETS, EXPANDING DISEASES

The early CAR-T story was focused on lupus. EULAR 2026 showed the field is now running parallel experiments across systemic sclerosis, inflammatory myopathy, and beyond — with dual CD19/BCMA targeting, shortened manufacturing platforms, off-the-shelf allogeneic options, and novel constructs like the E-CAR. Each approach is trying to answer the same question: can deeper or differently targeted B-cell depletion produce more durable remission than CD19 alone, and in diseases where CD19 has underperformed?

5 Years Since Patient ID001: Progress on CAR-T Therapy in RMD

CAR-T Cell Therapies in Refractory RMD

CAR-T Cell Therapies at EULAR 2026

How Many CAR-Ts Do We Need to Test Drive?

EULAR 2026 Daily Podcast Day 4a

Conclusions:

Dual CD19/BCMA targeting in Systemic Sclerosis produced 73% low disease activity with ILD stabilization in 11 patients — the most complete picture of CAR-T in scleroderma to date. Rapcabtagene Autoleucel cuts manufacturing from 14 days to 2, an important operational advance. The FT819 allogeneic platform showed sustained efficacy in SLE out to 24 months, with no GVHD. The novel E-CAR construct, incorporating the CD3ε cytoplasmic domain, produced deep tissue remission with fewer toxicities by recruiting physiologic negative regulators — the first attempt to engineer a safer signal transduction architecture from first principles. Gut microbiome data from zorpocabtagene autoleucel revealed that mucosal IgA at baseline may predict immune reconstitution kinetics — a finding with real implications for patient selection and monitoring. CD19 resets the B-cell compartment; whether that compartment is actually driving pathology varies substantially by RMD and by patient. The field is diversifying targets precisely because that ceiling is becoming visible.

III. WHEN CAR-T FAILS: RELAPSE BIOLOGY AND RESCUE STRATEGIES

Five years of CAR-T in autoimmunity has produced an inconvenient finding: it is not permanent. In the largest single-center series — 50 patients from Erlangen followed for over four years — 12% relapsed, overwhelmingly in inflammatory myopathy (3/8) and SSc (2/14), with only 1/28 lupus patients meeting the threshold. The relapses were sometimes severe: transverse myelitis, progressive ILD, worsening skin fibrosis. Retreatment with CD19 CAR-T failed. BCMA CAR-T and BCMA T-cell engagers rescued most of them — raising the uncomfortable question of whether BCMA should have been the first target in some disease contexts. The field now has immunologic data suggesting that pathogenic memory B cells can be detected in peripheral blood before clinical relapse, opening the door to preemptive monitoring.

Management of Relapses After CAR-T Therapy in SLE, SSc, and IIM

What Happens When CAR-T Fails: Managing Disease Recurrence

From Skepticism to Reconsideration: 4-Year CAR-T Outcomes in Lupus

EULAR 2026 Daily Podcast Day 2c

Daily Recap Day 1 + 2 EULAR 2026

Conclusions:

The 12% relapse rate in Erlangen's 50-patient series is not catastrophic — but the severity of those relapses is concerning. These included transverse myelitis and progressive ILD in patients who had just undergone lymphodepletion and CAR-T infusion. The observation that CD19 CAR-T re-infusion failed while BCMA therapies rescued is mechanistically clarifying: in some patients, the pathogenic antibody source resides in long-lived plasma cells in the bone marrow — compartments CD19 doesn't reach. The immunologic early-warning signal (atypical memory B cells detectable in blood before clinical flare) suggests that proactive monitoring protocols may eventually allow preemptive BCMA escalation rather than reactive rescue. For the 4-year SLE cohort — all 8 patients in sustained DORIS remission, infection rates declining over time — the durability story remains compelling in lupus, but numbers are still limited. But anti-synthetase myositis is emerging as the disease most likely to escape CD19-mediated reset, and will need further evaluation.

IV. IMMUNE DIMMING, T-CELL ENGAGERS, AND THE SCALABILITY PROBLEM

Not every patient who needs an immune reset can get one — manufacturing time, lymphodepletion, leukapheresis, and cost are real barriers that limit CAR-T to a handful of specialized centers. EULAR 2026 surfaced several approaches trying to solve that access problem: the T-cell engager blinatumomab (at low dose, without the oncology-grade toxicity), allogeneic NK cell therapy (AB101, potentially outpatient), and the emerging concept of "immune dimming" — a deliberate, partial reset that may restore drug responsiveness rather than aim for full drug-free remission. The blinatumomab data produced one of the meeting's most unexpected findings: patients who relapsed after "immune dimming" then responded to biologics they had previously failed.

5 Years Since Patient ID001: Progress on CAR-T Therapy in RMD

CAR-T Topic Compilation Podcast

Day 4 Recap EULAR 2026

Day 4 Recap: EULAR 2026

EULAR 2026 Rheumatology RoundUp

Conclusions:

Low-dose blinatumomab achieved 100% ACR20 and 73% ACR50 in refractory RA — but 93% relapsed by month 4, and lymph node B-cell depletion was consistently incomplete. The twist: after relapse, most patients responded to the biologics they had previously failed. This "immune dimming" concept — B-cell stunning rather than resetting — is either a legitimate partial intervention or a rationalization for a drug that doesn't work well enough. But the restored drug responsiveness is a genuinely novel observation that warrants controlled investigation. The AB101 NK cell platform achieved outpatient delivery with zero CRS and zero ICANS in a small RA cohort, with synovial B-cell depletion confirmed in 4/5 biopsied patients — but only moderate disease activity improvement, not remission. "Immune dimming" may serve a different clinical niche than full reset — not drug-free remission, but re-sensitization to previously failed therapies. That's a meaningful possibility for the polyrefractory patient sitting in clinic today.